Influence of Malondialdehyde and Matrix Metalloproteinase-9 on Progression of Carotid Atherosclerosis in Chronic Renal Disease with Cardiometabolic Syndrome
Table 1
Basal characteristics of monitored patients.
Control subjects (20)
CKD and PD pts (52)
CKD pts with eGFR < 60 > 15 mL/min/1.73 m2 (30)
PD pts (22)
Age (years)
57.8 ± 14.2
59.8 ± 161
>0.05
63.6 ± 15.1
54.7 ± 16.2
>0.05
Smokers (yes)
35%
46%
>0.05
52%
38%
>0.05
SBP (mmHg)
124 ± 8.68
140.5 ± 19.65
<0.01
135.3 ± 20.44
147.6 ± 16.4
<0.05
DBP (mmHg)
79.8 ± 5.5
90.5 ± 11.22
<0.05
83.7 ± 10.67
90.7 ± 11.21
<0.05
Hemoglobin (g/L)
146.3 ± 11.82
117.3 ± 22.48
<0.01
126.4 ± 23.92
104.7 ± 12.2
<0.01
Albumins (g/L)
37.6 ± 1.76
34.4 ± 6.02
>0.05
36.8 ± 5.83
31.1 ± 4.59
<0.01
CRP (mg/L)
2.8 ± 1.96
9.2 ± 8.81
<0.01
9.8 ± 9.15
8.4 ± 8.48
>0.05
Cholesterol (mmol/L)
5.2 ± 1.37
5.7 ± 0.81
>0.05
4.9 ± 1.35
5.8 ± 1.26
>0.05
Triglycerides (mmol/L)
1.9 ± 0.15
2.0 ± 1.19
>0.05
1.8 ± 0.79
2.4 ± 1.52
>0.05
Uric acid (µmol/L)
272.9 ± 53.1
362.7 ± 104.2
<0.01
364.7 ± 120.8
360 ± 79.9
<0.01
BMI (kg/m2)
22.3 ± 2.2
26.6 ± 2.95
>0.05
26.9 ± 3.7
25.7 ± 2.2
>0.05
MDA (ng/mL)
24.9 (12.3–26.9)
37 (24.1–47.7)
<0.01
37 (27–47.1)
35.9 (23.7–47.7)
>0.05
MMP-9 (ng/mL)
321.9 (24–370.9)
419.4 (350.9–447)
<0.01
420 (390.1–442)
390 (350.9–464)
>0.05
Results are expressed as mean ± standard deviation or median and interquartile range (25%–75%); pts: patients; CKD: chronic kidney disease; PD: peritoneal dialysis; SBP: systolic blood pressure; DBP: diastolic blood pressure; CRP: C-reactive protein; BMI: body mass index.
